Application of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Peripheral T-cell Lymphoma

Peripheral T-cell lymphoma (PTCL) is a subset of non-Hodgkin lymphoma that poses significant treatment challenges. Improving treatment strategies and prognosis for PTCL has been a major focus of research. Autologous hematopoietic stem cell transplantation (Auto-HSCT) has gained significant attention in recent years as a crucial therapeutic approach for PTCL. This paper reviews the literature and analyzes clinical data to explore the value, treatment process, efficacy evaluation, and management of complications associated with Auto-HSCT in PTCL. Studies indicate that Auto-HSCT can significantly improve disease-free survival (DFS) and overall survival (OS) in some PTCL patients, particularly those who undergo transplantation after initial remission. Additionally, this paper discusses the risk assessment and management strategies for complications arising during the transplantation process. The potential for combining Auto-HSCT with emerging therapies such as CAR-T cell therapy is also examined. Despite certain limitations, Auto-HSCT holds an indispensable role in the comprehensive treatment of PTCL and offers new directions for future research.